Key Highlights

  • IIPR reported third quarter 2026 Revenue of $64.9 million, compared with $64.7 million a year earlier.
  • Net income attributable to common stockholders was $28.7 million, or $0.99 per diluted share, against $0.97 a year earlier.
  • AFFO was $54.8 million, or $1.96 per share, up 7% from the second quarter of 2026 and from $1.71 a year ago.
  • The board declared a Dividend of $1.90 per common share, or $7.60 annualized, paid on Oct 15, 2026.
  • A $245.0 million mezzanine Loan Commitment on a Cambridge life science campus anchored $275 million of Investment activity.

AFFO Climbs to $1.96 Per Share as Net Income Edges Higher

Innovative Industrial Properties (NYSE:IIPR) reported results on Nov 2, 2026 for the third quarter ended Sep 30, 2026. The real estate investment trust owns specialized industrial properties, largely cannabis cultivation facilities, and has been adding life science real estate investments. Total revenues were $64.9 million, up 0.4% from $64.7 million a year earlier.

Net income attributable to common stockholders was $28.7 million, or $0.99 per diluted share, compared with $28.3 million, or $0.97. Normalized FFO was $50.2 million, or $1.80 per share, up from $1.60. AFFO reached $54.8 million, or $1.96 per share, which is about 14.6% above the $1.71 posted a year earlier (calculated).

Tenant Defaults and Lease Terminations Reshape the Cannabis Portfolio

During the quarter the company terminated 16 leases covering 1.2 million square feet and signed 6 new leases covering 604,000 square feet. After quarter end it signed a new lease for a 270,000 square foot property in Pennsylvania, contingent on cannabis license transfer approvals. Defaulted tenants contributed $11.6 million in payments and applied security deposits, or $0.41 per share, versus $10.5 million, or $0.35, in the second quarter.

All leases with one defaulted tenant have been terminated, and a new lease was signed for its former New York property. Three properties leased to another tenant represent 7.1% of annualized contractual rent, with replacement tenants lined up once receivership proceedings end, expected by year end 2026 or early 2027. The company also received full repayment of $49.0 million of seller financing in October.

The supplemental package showed 108 properties, 37 tenants and a 90% leased operating portfolio as of Sep 30, 2026.

A $245 Million Cambridge Life Science Loan Extends the Capital Deployment Push

In September the company committed $245.0 million to a mezzanine loan on a life science campus in Cambridge, Massachusetts, funding about $111.0 million at closing. The loan is expected to Yield roughly 15.8%, subject to a 14.0% floor, and matures in February 2028 with a one-year extension option. The remaining $134.0 million is expected to be funded through the fourth quarter of 2027.

It also funded $30.0 million of preferred Equity in the same sponsor, bringing its aggregate strategic investment to $300.0 million. Interest and other income rose by $9.9 million to $14.3 million, helped by $10.4 million from those investments. Interest expense climbed to $11.8 million from $4.5 million.

Low Leverage, a $1.90 Dividend and an Extended Credit Line Frame the Next Steps

At Sep 30, 2026, cash totaled $142.4 million, net Debt to total gross Assets was 18.7% and net debt to adjusted EBITDA was 2.1 times. After quarter end, the company raised $54.2 million of gross proceeds from a preferred stock offering and extended its $87.5 million revolving credit Facility to Jan 21, 2027. The next steps to watch are the funding of the remaining loan commitment, the outcome of receivership proceedings, and the conference call scheduled for Nov 3, 2026.